Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug;55(4):524-530.
doi: 10.1111/1475-6773.13285. Epub 2020 Mar 20.

Out-of-pocket costs and HIV pre-exposure prophylaxis persistence in a US multicity demonstration project

Nathan W Furukawa  1   2 , John A Schneider  3 , Megan E Coleman  4 , Jeffrey B Wiener  1 , Ram K Shrestha  1 , Dawn K Smith  1
Affiliations

Out-of-pocket costs and HIV pre-exposure prophylaxis persistence in a US multicity demonstration project

Nathan W Furukawa et al. Health Serv Res. 2020 Aug.

Abstract

Objective: To evaluate whether out-of-pocket (OOP) costs reduced HIV pre-exposure prophylaxis (PrEP) persistence.

Data source: Participants from five urban community health centers (CHCs) in four US cities enrolled in a PrEP demonstration project from September 2014 to August 2017.

Study design: Patients initiating PrEP were followed quarterly until they withdrew from PrEP care or the study ended. Self-reported OOP medication and clinic visit costs were assessed by semiannual questionnaires. Persistence was defined as the time from study enrollment to the last visit after which two subsequent 3-month visits were missed. Multivariable Cox proportional hazard regression was used to assess the effect of demographics, insurance, and OOP costs on PrEP persistence.

Principal findings: Among 918 participants with OOP cost data, the average quarterly OOP cost was $34 (median: $5, IQR: $0-$25). Participants who were men, White, employed, completed college, and had commercial insurance had higher OOP costs. Higher OOP costs were not associated with lower PrEP persistence by Cox proportional hazards regression (adjusted hazard ratio = 1.00 per $50 increase, 95% CI = 0.97, 1.02).

Conclusion: Among patients receiving care from these urban CHCs, OOP costs were low and did not undermine PrEP persistence.

Keywords: HIV prevention; community health clinic; out-of-pocket costs; persistence; pre-exposure prophylaxis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399‐410. - PMC - PubMed
    1. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double‐blind, placebo‐controlled phase 3 trial. Lancet. 2013;381(9883):2083‐2090. - PubMed
    1. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587‐2599. - PMC - PubMed
    1. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423‐434. - PubMed
    1. Hare CB, Coll J, Ruane P, et al. The Phase 3 DISCOVER Study: Daily F/TAF or F/TDF for HIV Pre‐Exposure Prophylaxis. Presented at: Conference on Retroviruses and Opportunistic Infections; 2019; Seattle, Washington, U.S.A.

Publication types